Literature DB >> 11878222

Validation of a heteroscedastic hazards regression model.

Hong-Dar Isaac Wu1, Fushing Hsieh, Chen-Hsin Chen.   

Abstract

A Cox-type regression model accommodating heteroscedasticity, with a power factor of the baseline cumulative hazard, is investigated for analyzing data with crossing hazards behavior. Since the approach of partial likelihood cannot eliminate the baseline hazard, an overidentified estimating equation (OEE) approach is introduced in the estimation procedure. It by-product, a model checking statistic, is presented to test for the overall adequacy of the heteroscedastic model. Further, under the heteroscedastic model setting, we propose two statistics to test the proportional hazards assumption. Implementation of this model is illustrated in a data analysis of a cancer clinical trial.

Entities:  

Mesh:

Year:  2002        PMID: 11878222     DOI: 10.1023/a:1013566631377

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  4 in total

1.  A regression survival model for testing the proportional hazards hypothesis.

Authors:  C Quantin; T Moreau; B Asselain; J Maccario; J Lellouch
Journal:  Biometrics       Date:  1996-09       Impact factor: 2.571

2.  Heterogeneity in survival analysis.

Authors:  O O Aalen
Journal:  Stat Med       Date:  1988-11       Impact factor: 2.373

3.  A two-sample censored-data rank test for acceleration.

Authors:  N E Breslow; L Edler; J Berger
Journal:  Biometrics       Date:  1984-12       Impact factor: 2.571

4.  A two-sample test sensitive to crossing hazards in uncensored and singly censored data.

Authors:  D M Stablein; I A Koutrouvelis
Journal:  Biometrics       Date:  1985-09       Impact factor: 2.571

  4 in total
  1 in total

1.  Tests for equality of survival distributions against non-location alternatives.

Authors:  Vilijandas B Bagdonavicius; Ruta J Levuliene; Mikhail S Nikulin; Olga Zdorova-Cheminade
Journal:  Lifetime Data Anal       Date:  2004-12       Impact factor: 1.588

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.